Neurocrine Biosciences (NBIX) Net Equity Issued and Repurchased (2010 - 2026)

Neurocrine Biosciences' Net Equity Issued and Repurchased history runs 17 years deep, the most recent figure standing at $23.6 million for Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 26.48% year-over-year to $23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $120.9 million (up 43.42% YoY) and the FY2025 annual result came in at $129.4 million, up 5.98% from the prior year.
• Net Equity Issued and Repurchased was $23.6 million for Q1 2026 at Neurocrine Biosciences, down from $37.3 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $69.9 million in Q1 2024 and bottomed at $2.6 million in Q2 2022.
• A 5-year average of $22.7 million and a median of $18.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased jumped 1266.67% — and 2024, when it plunged 71.75%.
• Neurocrine Biosciences' Net Equity Issued and Repurchased stood at $24.6 million in 2022, then surged by 43.9% to $35.4 million in 2023, then sank by 71.75% to $10.0 million in 2024, then surged by 273.0% to $37.3 million in 2025, then slumped by 36.73% to $23.6 million in 2026.
• Business Quant data shows NBIX's Net Equity Issued and Repurchased at $23.6 million in Q1 2026, $37.3 million in Q4 2025, and $45.6 million in Q3 2025.